Xin Hua Cai Jing·2025-07-25 06:22Core Viewpoint - The CXO (Contract Research Organization) sector is experiencing a significant performance improvement, driven by favorable policies and increased demand for innovative drug development in China [1][4]. Group 1: Industry Performance - CXO concept stocks have shown strong activity, with companies like Boteng Co. rising nearly 10% and others like Kanglong Chemical and Yiqiao Shenzhou increasing over 5% [1]. - WuXi AppTec and Boteng Co. have reported mid-year performance forecasts that confirm the trend of improving performance in CXO companies, indicating a potential reversal in industry prosperity [1][2]. - The overall order volume in the CXO industry has shown positive growth, with KaiLaiYing reporting a 20% increase in new orders for 2024 and Kanglong Chemical's laboratory services seeing over 15% growth [3]. Group 2: Company-Specific Insights - WuXi AppTec expects to achieve approximately 20.64% revenue growth year-on-year for the first half of 2025, with adjusted net profit expected to grow by 44.43% [2]. - Boteng Co. anticipates a revenue increase of 15% to 20% for the first half of 2025, marking a significant turnaround to profitability [2][3]. - The improvement in Boteng Co.'s gross margin and overall profitability is attributed to strict cost control and enhanced operational efficiency [3]. Group 3: Market Trends and Valuation - The CXO sector is poised for a "Davis Double Play," where both profitability and valuation are expected to rise simultaneously due to improved demand and a recovering investment environment [4]. - The current valuation of the CXO sector is at a mid-low level compared to historical highs, suggesting potential for upward movement as the market stabilizes [4]. - Analysts predict that the demand for innovative drug development will continue to grow, particularly in the context of new technologies like ADCs (Antibody-Drug Conjugates) [5].